About Us

We believe that combining innovative technology with clinical application is key to advancing cancer treatment. Our commitment includes:

• Targeting Tumors, Protecting Health: Developing highly selective oncolytic viruses that attack tumors while minimizing harm to healthy tissues for safer, more effective treatments.
• Activating the Immune System: Creating therapies that stimulate a lasting anti-cancer immune response, reducing recurrence and offering long-term benefits.
• Improving Quality of Life: Reducing side effects to enhance patients’ well-being throughout treatment.
• Driving Scientific Progress: Collaborating globally to translate cutting-edge research into clinical advances.

Vision: To lead globally in cancer treatment, delivering hope and breakthroughs for patients through innovation.

Action Mechanism of Oncolytic Virus

How oncolytic  virus  kills tumor cells

• Selective Replication in Cancer CellsTarget
  • cancer cells due to altered signaling.
  • Exploit cancer cell vulnerabilities for replication.
• Cell Lysis and Viral Release
  • Replicated virus causes cancer cell lysis.
  • Releases new viral particles into the tumor microenvironment.
• Stimulation of Immune Responses
  • Viral components attract immune cells.
  • Induces a local immune response against cancer.
• Anti-Angiogenic Effects
  • Inhibits angiogenesis, limiting tumor blood supply.
  • Impairs tumor growth by disrupting blood vessel formation.
• Expression of Therapeutic Transgenes
  • Engineered to express therapeutic genes.
  • Enhances direct cytotoxic effects or modulates the immune response.
• Clinical Implications
  • Used in cancer therapy, e.g., talimogene laherparepvec (T-VEC) for melanoma.
  • Demonstrates potential for targeted and immunotherapeutic cancer treatment.